Skip to content
DraconiticResearch
Search Sources API
203,948 studies31 sourcesUpdated 10 min ago
Peer-reviewedCC BYInternational journal of molecular sciences

ANXA2 as a Candidate Molecular Hub Linking Fibrinolysis, Coagulation, and Immune Remodeling in Hepatocellular Carcinoma: An Integrative Multi-Omics Analysis

  • Esra’a Abudouleh1
  • Rasha Elsayim1
  • Heba W. Alhamdi2
  • Nada Fahad Almebairik3
  • Noorah A. Alkubaisi1
  1. 1Department of Botany and Microbiology, College of Science, King Saud University, P.O. Box 2455, Riyadh 11451, Saudi Arabia
  2. 2Department of Biology, College of Sciences, King Khalid University, P.O. Box 960, Abha 61413, Saudi Arabia
  3. 3Department of Clinical Laboratory Science, College of Applied Medical Sciences, King Saud University, P.O. Box 10219, Riyadh 11433, Saudi Arabia
Read full textPDFDOICite

Abstract

Annexin A2 (ANXA2) is involved in cell-surface fibrinolysis and has been associated with hepatocellular carcinoma (HCC). We examined ANXA2 expression in HCC and its associations with survival and immune–hemostatic gene expression. ANXA2 transcript expression was assessed in The Cancer Genome Atlas liver cancer cohort (TCGA-LIHC) and an independent HCC dataset (GSE25097). Public protein datasets were used to examine ANXA2 abundance. We analyzed clinicopathological associations, overall survival, tumor–normal tissue discrimination, and correlations with selected immune, coagulation, fibrinolytic, and inflammatory genes. ANXA2 expression was higher in HCC than in non-tumor liver tissue in the transcriptomic analyses and was elevated in the protein analyses. Higher ANXA2 expression was associated with poorer overall survival after adjustment for age, sex, and pathological stage (hazard ratio, 1.26; 95% confidence interval, 1.07–1.49; p = 0.006). Within TCGA-LIHC, ANXA2 expression discriminated tumor from normal tissue (area under the curve, 0.895; 95% confidence interval, 0.852–0.933); this performance was not independently validated. ANXA2 expression also correlated with selected fibrinolytic, inflammatory, and immune-related genes. GSE25097 supported the differential-expression finding. ANXA2 is overexpressed in HCC and is associated with poorer survival and an immune–hemostatic transcriptional pattern. The correlations do not establish that ANXA2 regulates these processes.

Related

  1. Coagulation and Fibrinolysis in Normal Pregnancy and Complicated Pregnancy
    Yang Su, Yao Wei, Cheng Liu +4
    International Journal of Laboratory HematologyPeer-reviewedCC BY-NC-ND 4.0Full textObstetrics, gynaecology & paediatricsPMC
  2. Coagulation and fibrinolysis biomarkers associated with gastrointestinal bleeding in children with immunoglobulin A vasculitis: a retrospective cohort study.
    Fang Chen, Hanjun Shen, Xuejun Shao +1
    Frontiers in pediatricsPeer-reviewedCC BYFull textGeneral medicineEurope PMCPMC
  3. CO070 | PLASMIN GENERATION AND ITS INTERPLAY WITH COAGULATION AND FIBRINOLYSIS IN ATRIAL FIBRILLATION: IMPACT OF ANTICOAGULANT THERAPY
    Giulia Ciarrocca Taranta
    Bleeding, Thrombosis and Vascular BiologyPeer-reviewedCC BY-NCFull textCardiovascular medicineDOAJ
  4. Integrative Multi-Database Bioinformatics Characterization of FANCE in Hepatocellular Carcinoma: Prognostic, Epigenetic, Immune, and ncRNA Associations
    Yeong Chae Kim, Kyu-Shik Lee, Hye-Ran Kim +1
    Medicina (Kaunas, Lithuania)Peer-reviewedCC BYFull textGeneral medicineEurope PMC
  5. ASIC1 Emerges as an ATC-Associated Candidate from an Integrative Dual miRNA-mRNA Analysis
    Berrin Ozdil, Hatice Ozisik
    BiomedicinesPeer-reviewedCC BYFull textGeneral medicineEurope PMC

Cite

BibTeXRIS
BibTeX
@article{abudouleh2026anxa2,
  title = {{ANXA2 as a Candidate Molecular Hub Linking Fibrinolysis, Coagulation, and Immune Remodeling in Hepatocellular Carcinoma: An Integrative Multi-Omics Analysis}},
  author = {Esra’a Abudouleh and Rasha Elsayim and Heba W. Alhamdi and Nada Fahad Almebairik and Noorah A. Alkubaisi},
  journal = {International journal of molecular sciences},
  year = {2026},
  month = oct,
  doi = {10.3390/ijms27198915},
  url = {https://europepmc.org/article/PMC/PMC13666242},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - ANXA2 as a Candidate Molecular Hub Linking Fibrinolysis, Coagulation, and Immune Remodeling in Hepatocellular Carcinoma: An Integrative Multi-Omics Analysis
AU  - Esra’a Abudouleh
AU  - Rasha Elsayim
AU  - Heba W. Alhamdi
AU  - Nada Fahad Almebairik
AU  - Noorah A. Alkubaisi
PY  - 2026
DA  - 2026/10/01
JO  - International journal of molecular sciences
DO  - 10.3390/ijms27198915
UR  - https://europepmc.org/article/PMC/PMC13666242
AB  - Annexin A2 (ANXA2) is involved in cell-surface fibrinolysis and has been associated with hepatocellular carcinoma (HCC). We examined ANXA2 expression in HCC and its associations with survival and immune–hemostatic gene expression. ANXA2 transcript expression was assessed in The Cancer Genome Atlas liver cancer cohort (TCGA-LIHC) and an independent HCC dataset (GSE25097). Public protein datasets were used to examine ANXA2 abundance. We analyzed clinicopathological associations, overall survival, tumor–normal tissue discrimination, and correlations with selected immune, coagulation, fibrinolytic, and inflammatory genes. ANXA2 expression was higher in HCC than in non-tumor liver tissue in the transcriptomic analyses and was elevated in the protein analyses. Higher ANXA2 expression was associated with poorer overall survival after adjustment for age, sex, and pathological stage (hazard ratio, 1.26; 95% confidence interval, 1.07–1.49; p = 0.006). Within TCGA-LIHC, ANXA2 expression discriminated tumor from normal tissue (area under the curve, 0.895; 95% confidence interval, 0.852–0.933); this performance was not independently validated. ANXA2 expression also correlated with selected fibrinolytic, inflammatory, and immune-related genes. GSE25097 supported the differential-expression finding. ANXA2 is overexpressed in HCC and is associated with poorer survival and an immune–hemostatic transcriptional pattern. The correlations do not establish that ANXA2 regulates these processes.
SN  - 1422-0067
ER  -